676 related articles for article (PubMed ID: 10935988)
21. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
22. Varicella vaccination in children with steroid-sensitive nephrotic syndrome.
Alpay H; Yildiz N; Onar A; Temizer H; Ozçay S
Pediatr Nephrol; 2002 Mar; 17(3):181-3. PubMed ID: 11956856
[TBL] [Abstract][Full Text] [Related]
23. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
24. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
Goldman GS
Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
[TBL] [Abstract][Full Text] [Related]
25. [Complications in two children with acute lymphatic leukemia caused by vaccination against varicella zoster virus].
Christensen CL; Poulsen A; Böttiger B; Kirk M; Andersen HK; Schmiegelow K
Ugeskr Laeger; 1999 Feb; 161(6):794-6. PubMed ID: 10068350
[TBL] [Abstract][Full Text] [Related]
26. Prospects for use of a varicella vaccine in adults.
Hardy IR; Gershon AA
Infect Dis Clin North Am; 1990 Mar; 4(1):159-73. PubMed ID: 2155261
[TBL] [Abstract][Full Text] [Related]
27. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M
J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376
[TBL] [Abstract][Full Text] [Related]
28. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward.
Asano Y; Nakayama H; Yazaki T; Ito S; Isomura S
Pediatrics; 1977 Jan; 59(1):8-12. PubMed ID: 190584
[TBL] [Abstract][Full Text] [Related]
29. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
31. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination.
Jenke AC; Klein S; Baiker A; Wirth S; Sander M; Noelting C; Boecher O; Vizoso-Pinto MG
Pediatr Infect Dis J; 2012 Nov; 31(11):1148-52. PubMed ID: 22863912
[TBL] [Abstract][Full Text] [Related]
32. Development of varicella vaccine.
Takahashi M; Asano Y; Kamiya H; Baba K; Ozaki T; Otsuka T; Yamanishi K
J Infect Dis; 2008 Mar; 197 Suppl 2():S41-4. PubMed ID: 18419406
[TBL] [Abstract][Full Text] [Related]
33. Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects.
Wittek AE; Arvin AM; Koropchak CM
J Clin Microbiol; 1983 Nov; 18(5):1146-9. PubMed ID: 6315766
[TBL] [Abstract][Full Text] [Related]
34. Prevention of shingles by varicella zoster virus vaccination.
Holodniy M
Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624
[TBL] [Abstract][Full Text] [Related]
35. Perspective on live varicella vaccine.
Gershon AA; Katz SL
J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
[TBL] [Abstract][Full Text] [Related]
36. Zoster vaccine: current status and future prospects.
Oxman MN
Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
[TBL] [Abstract][Full Text] [Related]
37. Vaccination of children with malignant disease against varicella.
Slørdahl SH; Wiger D; Strømøy T; Degre M; Thørsby E; Lie SO
Postgrad Med J; 1985; 61 Suppl 4():85-92. PubMed ID: 3014484
[TBL] [Abstract][Full Text] [Related]
38. Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity.
Otani N; Baba K; Okuno T
J Immunol Methods; 2009 Dec; 351(1-2):71-4. PubMed ID: 19818791
[TBL] [Abstract][Full Text] [Related]
39. Rapid molecular discrimination between infection with wild-type varicella-zoster virus and varicella vaccine virus.
Lässker U; Harder TC; Hufnagel M; Suttorp M
Infection; 2002 Oct; 30(5):320-2. PubMed ID: 12382096
[TBL] [Abstract][Full Text] [Related]
40. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.
Chaves Tdo S; Lopes MH; de Souza VA; Dos Santos Sde S; Pereira LM; Reis AD; David-Neto E
Pediatr Transplant; 2005 Apr; 9(2):192-6. PubMed ID: 15787792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
